95-4596354 · Beverly Hills, CA
INNOVATIVE RESEARCH, COMMUNITY EDUCATION AND CARING PATIENT SUPPORT WHILE DEVELOPING MORE EFFECTIVE TREATMENTS FOR CANCER AND BLOOD DISORDERS.
Total revenue
$2.5M
FY2023
Total expenses
$3.2M
FY2023
Net assets
$1.4M
FY2023
Operating margin
-25%
NPLens analysis
FY18–FY2023 · from annual filings
Financial health
D
Derived analysis — not an official IRS designation.
Computed from FY2023 · derived analysis
FY2023 · program vs. administration vs. fundraising (Form 990, Part IX)
FY2023 · where revenue comes from (as reported)
Highest-paid officers, directors & key employees · FY2023.
STEVEN ABRAMSON
EXECUTIVE DIRECTOR (THRU 9/30/23)
$195,384
KELLI SARGENT
DEPUTY DIRECTOR
$118,616
LINDA DAVID
EXECUTIVE DIRECTOR
$51,417
NANCY ROSENFELT
CHAIRMAN OF THE BOARD
$0
LARRY ROSENSTEIN
VICE CHAIR
$0
Each figure on this page traces to one of these source returns.
Health scores, efficiency ratios, peer percentiles, and outlier flags are derived analysis by NPLens — not official IRS designations. Figures are as reported on the organization's Form 990 filings. How these are computed →